Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lanreotide acetate + Octreotide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lanreotide acetate | Somatuline Depot | Lantreotide depot|AT-1001 | Somatuline Depot (lantreotide acetate) is a somatostatin analog peptide-based drug, which may decrease growth of neuroendocrine tumors (PMID: 27619395, PMID: 25014687). Somatuline Depot (lantreotide acetate) is FDA approved for use in gastroenteropancreatic neuroendocrine tumors (FDA.gov). | |
Octreotide | Atrigel | Octreotida [Spanish] |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03289741 | FDA approved | Lanreotide acetate + Octreotide | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | Completed | USA | 0 |